Amphetamine was discovered over 100 years ago. Since then, it has transformed from a drug that was freely available without prescription as a panacea for a broad range of disorders into a highly restricted Controlled Drug with therapeutic applications restricted to attention deficit hyperactivity disorder (ADHD) and narcolepsy. This review describes the relationship between chemical structure and pharmacology of amphetamine and its congeners. Amphetamine’s diverse pharmacological actions translate not only into therapeutic efficacy, but also into the production of adverse events and liability for recreational abuse. Accordingly, the balance of benefit/risk is the key challenge for its clinical use. The review charts advances in pharmaceutical development from the introduction of once-daily formulations of amphetamine through to lisdexamfetamine, which is the first d-amphetamine prodrug approved for the management of ADHD in children, adolescents and adults. The unusual metabolic route for lisdexamfetamine to deliver d-amphetamine makes an important contribution to its pharmacology. How lisdexamfetamine’s distinctive pharmacokinetic/pharmacodynamic profile translates into sustained efficacy as a treatment for ADHD and its reduced potential for recreational abuse is also discussed.
AdlerLAGoodmanDWKollinsSH. (2008) Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiat69: 1364–1373.
3.
AdlerLAWeislerRHGoodmanDW. (2009) Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiat70: 1652–1661.
4.
American Psychiatric Association (1994) The diagnostic and statistical manual of mental disorders, fourth edition. Arlington, VA: American Psychiatric Association.
5.
ArnoldLEHuestisRDSmeltzerDJ. (1976) Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch Gen Psychiat33: 292–301.
6.
ArnoldLEKirilcukVSamuelA. (1973) Levoamphetamine and dextroamphetamine: Differential effect on aggression and hyperkinesis in children and dogs. Am J Psychiat130: 165–170.
7.
ArnoldLEWenderPHMcCloskeyMM. (1972) Levoamphetamine and dextroamphetamine: Comparative efficacy in hyperkinetic syndrome. Arch Gen Psychiat27: 816–822.
8.
ArnstenAFDudleyAG (2005) Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct1: 2.
9.
BaumannMHAyestasMADerschCM. (2000) Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications. Synapse36: 102–113.
10.
BettWR (1946) Benzedrine sulphate in clinical medicine: A survey of the literature. Postgrad Med J22: 205–218.
11.
BiedermanJBoellnerSWChildressA. (2007a) Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiat62: 970–976.
12.
BiedermanJKrishnanSZhangY. (2007b) Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther29: 450–463.
13.
BiedermanJWigalSBSpencerTJ. (2006) A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther28: 280–293.
14.
Bolden-WatsonCRichelsonE (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci52: 1023–1029.
15.
BradleyC (1937) Behaviour of children receiving Benzedrine. Am J Psychiat94: 577–585.
16.
BredelouxPDubucICostentinJ (2007) Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol150: 711–719.
17.
BymasterFPKatnerJSNelsonDL. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology27: 699–711.
18.
CadoniCPinnaARussiG. (1995) Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry. J Neurosci65:1027–1039.
19.
CastellanosFX (2001) Neuroimaging studies of ADHD. In: SolantoMVArnstenAFCastellanosFX (eds) Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press, pp.243–258.
20.
CastellanosFXGieddJNMarshWL. (1996) Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiat53: 607–616.
21.
CharnaudBGriffithsV (1998) Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: A comparison. Drug Alcohol Depend52: 79–84.
22.
CheethamSCKulkarniRSRowleyHL. (2007) The SH rat model of ADHD has profoundly different catecholaminergic responses to amphetamine’s enantiomers compared with Sprague-Dawleys. Society for Neurosciences. Abstract 386.14. Available online at: www.sfn.org (accessed August 2012).
23.
ConnellPH (1966). Clinical manifestations and treatment of amphetamine type of dependence. JAMA196: 718–723.
24.
Di ChiaraGImperatoA (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA85: 5274–5278.
25.
Das-DouglasMColfaxGMossAR. (2008). Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996–2003. J Urban Health85: 239–249.
DewREKollinsSH (2010) Lisdexamfetamine dimesylate: A new option in stimulant treatment for ADHD. Expert Opin Pharmacother11: 2907–2913.
28.
DonnellyMRapoportJLPotterWZ. (1989) Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. Arch Gen Psychiat46: 205–212.
29.
DurstonS (2003) A review of the biological bases of ADHD: What have we learned from imaging studies?Ment Retard Dev Disabil Res Rev9: 184–195.
30.
EastonNStewardCMarshallF. (2007) Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology52: 405–414.
31.
ErmerJCDennisKHaffeyMB. (2011) Intranasal versus oral administration of lisdexamfetamine dimesylate: A randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig31: 357–370.
32.
ErmerJHomolkaRMartinP. (2010) Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol50: 1001–1010.
33.
ErnstMZametkinAJMatochikJA. (1998) DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci18: 5901–5907.
34.
FaraoneSVBuitelaarJ (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiat19: 353–364.
35.
FaraoneSVBiedermanJSpencerTJ. (2006) Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed8: 4.
36.
FaraoneSVWigalSBHodgkinsP (2007) Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Attent Disord11: 74–82.
37.
FeiHGrygorukABrooksES. (2008) Trafficking of vesicular neurotransmitter transporters. Traffic9: 1425–1436.
38.
FindlingRLChildressACKrishnanS. (2008) Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr13: 614–620.
39.
FleckensteinAEVolzTJHansonGR (2009) Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications. Neuropharmacology56: 133–138.
40.
FowlerJSVolkowNDLoganJ. (2008) Fast uptake and long-lasting binding of methamphetamine in the human brain – comparison with cocaine. Neuroimage43: 756–763.
41.
GérantonSMHealDJStanfordSC (2003) Differences in the mechanisms that increase noradrenaline efflux after administration of d-amphetamine: A dual-probe microdialysis study in rat frontal cortex and hypothalamus. Brit J Pharmacol139: 1441–1448.
42.
GilbertDCooperSJ (1983) β-Phenylethylamine-, d-amphetamine- and l-amphetamine-induced place preference conditioning in rats. Eur J Pharmacol95: 311–314.
43.
GlaserPEThomasTCJoyceBM. (2005) Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psychopharmacology (Berl)178: 250–258.
44.
GoodmanDWGinsbergLWeislerRH. (2005) An interim analysis of the quality of life, effectiveness, safety, and tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr10: 26–34.
45.
GreenhillLLSwansonJMSteinhoffK. (2003) A pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiat42:1234–1241.
GrossMD (1976). A comparison of d-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction. Dis Nerv Sys37: 14–16.
48.
GundlahCMartinKFHealDJ. (1997) In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther283: 581–591.
49.
GustavssonASvenssonMJacobiF.; CDBE2010Study Group (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol21: 718–79.
50.
GuttmannESargentW (1937) Observations on Benzedrine. Brit Med J1: 1013–1015.
51.
HamiltonMJSmithPRPeckAW (1983) Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electro-encephalogram in healthy volunteers. Br J Clin Pharmacol15: 367–374.
52.
HealDJCheethamSCProwMR. (1998) A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol125: 301–308.
53.
HealDJCheethamSCSmithSL (2009) The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety. Neuropharmacology57: 608–618.
54.
HealDJSmithSLFindlingRL (2012) ADHD: Current and future therapeutics. Curr Top Behav Neurosci9: 361–390.
55.
HealDJSmithSLKulkarniRS. (2008) New perspectives from microdialysis studies in freely moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav90: 184–197.
56.
HeikkilaREOrlanskyHMytilineouC. (1975) Amphetamine: Evaluation of d- and l-isomers as releasing agents and uptake inhibitors for [3H]dopamine and [3H]norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther194: 47–56.
57.
HitriAVenableDNguyenHQ. (1991) Characteristics of [3H]GBR 12935 binding in the human and rat frontal cortex. J Neurochem56: 1663–1672.
58.
HolmesJCRutledgeCO (1976) Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. Biochem Pharmacol25: 447–451.
59.
HowlandRH (2008) Lisdexamfetamine: A prodrug stimulant for ADHD. J Psychosoc Nurs Ment Health Serv46: 19–22.
60.
HuestisRDArnoldLESmeltzerDJ (1975) Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: A double-blind comparison. Am J Psychiat132: 868–870.
61.
JacksonHCRowleyHLHackettD. (2011) Comparison of the effects of equivalent doses of lisdexamfetamine dimesylate and d-amphetamine on extracellular concentrations of striatal dopamine, locomotor activity and plasma amphetamine concentrations in freely moving rats. Abstract number 775.23. Available at: http://www.SfN.org (accessed August 2012).
62.
JamesRSSharpWSBastainTM. (2001) Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiat40: 1268–1276.
63.
JasinskiD (2005) A double-blind placebo- and active-controlled, single-dose crossover pharmacodynamic and pharmacokinetic study to evaluate the safety, tolerability and abuse liability of intravenously administered NRP104 25 mg and 50 mg in healthy adult volunteers with histories of stimulant abuse. Protocol No: NRP104.A02. Available at: http://clinicaltrials.gov/ct2/show/NCT00247572 (accessed August 2012).
64.
JasinskiDR (2006) A double-blind, randomized, placebo and active-controlled, six-period crossover study to evaluate the likeability, safety, and abuse liability of NRP104 in healthy adult volunteers with histories of stimulant abuse. Protocol No: NRP104.A03. Available at: http://clinicaltrials.gov/show/NCT00248092 (accessed August 2012).
65.
JasinskiDRKrishnanS (2009a) Human pharmacology of intravenous lisdexamfetamine dimesylate: Abuse liability in adult stimulant abusers. J Psychopharmacol23: 410–418.
66.
JasinskiDRKrishnanS (2009b) Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol23: 419–427.
67.
JoyceBMGlaserPEAGerhardtGA (2007) Adderall® produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Psychopharmacology (Berl)191: 669–677.
68.
KällKIOlinRG (1990) HIV status and changes in risk behaviour among intravenous drug users in Stockholm 1987–1988. AIDS4: 153–157.
69.
KooijSJBejerotSBlackwellA. (2010) European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiat10: 67.
70.
KrishnanSMStarkJG (2008) Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin24: 33–40.
71.
KrishnanSMPennickMStarkJG (2008) Metabolism, distribution and elimination of lisdexamfetamine dimesylate. Open label, single-centre, Phase I study in healthy adult volunteers. Clin Drug Invest28: 745–755.
72.
KuczenskiRSegalDSChoAK. (1995) Hippocampus norephinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci15: 1308–1317.
73.
KulaNSBaldessariniRJ (1991) Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. Neuropharmacology30: 89–92.
74.
LeinoTLeinikkiPHyypiäT. (1997) Hepatitis: An outbreak amongst intravenous amphetamine abusers in Finland. Scand J Infect Dis29: 213–216.
75.
LopezFAGinsbergLDArnoldV (2008) Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: A secondary analysis. Postgrad Med120: 89–102.
MaisonneuveIMKellerRWGlickSD (1990) Similar effects of d-amphetamine and cocaine on extracellular dopamine levels in medial prefrontal cortex of rats. Brain Res535: 221–226.
78.
MantleTJTiptonKFGarrettNJ (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol25: 2073–2077.
79.
MattinglyG (2010) Lisdexamfetamine dimesylate: A prodrug stimulant for the treatment of ADHD in children and adults. CNS Spectr5: 315–325.
80.
MazeiMSPlutoCPKirkbrideB. (2002) Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res936: 58–67.
81.
Merck Index, Ninth Edition (1976) WindholzMBudavariSStroumtososLYFertigMN (eds) An Encyclopaedia of Chemicals and Drugs. Rahway, NJ, USA: Merck & Co., Inc.
82.
MerkelRLJrKuchibhatlaA (2009) Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. Expert Opin Drug Saf8: 655–668.
83.
MillerLGriffithJ (1983) Comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology80: 199–205.
84.
MillerHHShorePAClarkeDE (1980) In vivo monoamine oxidase inhibition by d-amphetamine. Biochem Pharmacol29: 1347–1354.
85.
MorónJABrockingtonAWiseRA. (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci22: 389–395.
86.
NajibJ (2009) The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther31: 142–176.
87.
NomikosGGDamsmaGWenksternD. (1989) Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology2: 273–279.
88.
NomikosGGDamsmaGWenksternD. (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse6: 106–112.
89.
PeckAWByeCEClubleyM. (1979) A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br J Clin Pharmacol7: 469–478.
90.
PelhamWEBurrows-MacleanLGnagyEM. (2005). Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol13: 111–126.
91.
PelhamWEGnagyEMChronisAM. (1999) A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics104: 1300–1311.
92.
PelhamWEGreensladeKEVodde-HamiltonM. (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics86: 226–237.
93.
PennickM (2010) Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat24: 317–327.
94.
PumMCareyRJHustonJP. (2007) Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats. Psychopharmacology (Berl)193: 375–390.
95.
RamamoorthySShippenbergTSJayanthiLD (2011) Regulation of monoamine transporters: Role of transporter phosphorylation. Pharmacol Ther129: 220–238.
96.
RasmussenN (2008) America’s first amphetamine epidemic 1929–1971. A quantitative and qualitative retrospective with implications for the present. Am J Public Health98: 974–985.
97.
RichelsonEPfenningM (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol104: 227–286.
98.
RisnerME (1975) Intravenous self-administration of d- and l-amphetamine by dogs. Eur J Pharmacol32: 344–348.
99.
RobertsonSDMatthiesHJGalliA (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol39: 73–80.
100.
RobinsonJB (1985) Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, n-methylamphetamine and deprenyl. Biochem Pharmacol34: 4105–4108.
101.
RothmanRBBaumannMHDerschCM. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse39: 32–41.
102.
RowleyHLButlerSAProwMR. (2000) Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse38: 167–176.
103.
RowleyHLCheethamSCHackettD. (2011) Lisdexamfetamine dimesylate versus d-amfetamine – Hysteresis analyses of the relationships between extracellular striatal dopamine and locomotor activity measured in freely moving-rats. Abstract number 775.11. Available at: http://www.SfN.org (accessed August 2012).
SagvoldenT (2000) Behavioural validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev24: 31–39.
106.
SagvoldenTJohansenEBWøienG. (2009) The spontaneously hypertensive rat model of ADHD – the importance of selecting the appropriate reference strain. Neuropharmacology57: 619–626.
107.
SagvoldenTRussellVAAaseH. (2005) Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiat57: 1239–1247.
108.
SchechterMD (1978) Stimulus properties of d-amphetamine as compared to l-amphetamine. Eur J Pharmacol47: 461–464.
109.
ScraggsPRRidleyRM (1978) Behavioural effects of amphetamine in a small primate: Relative potencies of the d- and d-isomers. Psychopharmacology (Berl)59: 243–245.
110.
ShoblockJRMaisonneuveIMGlickSD (2004) Differential interactions of desipramine with amphetamine and methamphetamine: Evidence that amphetamine releases dopamine from noradrenergic neurons in the medial prefrontal cortex. Neurochem Res29: 1437–1442.
111.
ShoblockJRSullivanEBMaisonneuveIM. (2003) Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl)165: 359–369.
112.
SidhpuraNRedfernPRowleyH. (2007) Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo.Biochem Pharmacol74: 1292–1298.
SmithRCDavisJM (1977) Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. Psychopharmacology (Berl)53: 1–12.
115.
SøgaardUMichalowJButlerB. (1990) A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR12909 in healthy subjects. Int Clin Psychopharmacol5: 237–251.
116.
StahlSM (2003) Neurotransmission of cognition, part 1. Dopamine is a hitchhiker in frontal cortex: Norepinephrine transporters regulate dopamine. J Clin Psychiat64: 230–231.
117.
SwansonCJPerryKWKoch-KruegerS. (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology50: 755–760.
118.
TaoRFrayAAspleyS. (2002) Effects on serotonin in rat hypothalamus of d-fenfluramine, aminorex, phentermine and fluoxetine. Eur J Pharmacol445: 69–81.
119.
TengLCrooksPADwoskinLP (1998) Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: Comparison with d-amphetamine. J Neurochem71: 258–265.
120.
TidyHL (1938) Discussion on benzedrine: Uses and abuses. Proc R Soc Med32: 385–398.
121.
Van KammenDPMurphyDL (1975) Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia44: 215–224.
122.
VolkowNDSwansonJM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiat160: 1909–1918.
123.
VolkowNDWangG-JFoltinRW. (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature386: 827–830.
124.
VolkowNDWangG-JFowlerJS. (1996b) Relationship between psychostimulant-induced “high” and dopamine transporter occupancy. Proc Natl Acad Sci93: 10388–10392.
125.
VolkowNDWangG-JFowlerJS. (1999a) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exp Ther291: 409–415.
126.
VolkowNDWangG-JFowlerJS. (1999b) Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of “high”. J Pharmacol Exp Ther288: 14–20.
127.
VolkowNDWangG-JGatleySJ. (1996a) Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioural and cardiovascular effects. Psychopharmacology (Berl)123: 26–33.
WeislerRYoungJMattinglyG. (2009) Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention deficit/hyperactivity disorder. CNS Spectr14: 573–585.
130.
WesterinkBHCDamsmaGDe VriesJB. (1987) Dopamine reuptake inhibitors shown inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat. Eur J Pharmacol135: 123–128.
131.
WickensJRHylandBITrippG (2011) Animal models to guide clinical drug development in ADHD: Lost in translation?Br J Pharmacol164: 1107–1128.
132.
WigalTBramsMGasiorM. (2010a) Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: Novel findings using a simulated adult workplace environment design. Behav Brain Funct6: 34.
133.
WigalSBKollinsSHChildressAC. (2009) A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiat Ment Health3: 17.
134.
WigalSBKollinsSHChildressAC. (2010b) Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: Sex and age effects and effect size across the day. Child Adolesc Psychiat Ment Health4: 32.
135.
WigalSBMcGoughJJMcCrackenJT. (2005) A laboratory school comparison of mixed amphetamine salts extended release (Adderal XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord9: 275–289.
136.
WinsbergBGPressMBialerI. (1974) Dextroamphetamine and methylphenidate in the treatment of hyperactive/aggressive children. Pediatrics53: 236–241.
137.
WittchenHUJacobiFRehmJ. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol21: 655–679.
138.
YokelRAPickensR (1973) Self-administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther187: 27–33.
